SCHEMBL18060648

SCHEMBL18060648

COc1nc(N2CCOCC2)nc(OC)c1Sc1cccc(N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK4 O00444 1/20 0.46
▸ MAPT P10636 3/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP2C9 P11712 2/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ PIK3CA P42336 10/20 0.42
▸ MTOR P42345 4/20 0.42
▸ HSD17B10 Q99714 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ PIK3R1 P27986 1/20 0.40
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ TSHR P16473 2/20 0.40
▸ PIK3CD O00329 3/20 0.39
▸ PIK3CB P42338 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1276351 0.87 ADRA2C (0.46) L3MBTL1MEN1KMT2A
SCHEMBL18060958 0.79 PIK3CA (0.47) MAPTPIK3CAMTORHSD17B10KDM4E
SCHEMBL12936268 0.78 ADRA2C (0.42) MEN1KMT2A
SCHEMBL18060670 0.78 KCNQ3 (0.47) MAPTCYP3A4PIK3CAALDH1A1L3MBTL1
SCHEMBL18060894 0.77 SMN1; SMN2 (0.43) MAPTCYP3A4PIK3CAMTORHSD17B10
SCHEMBL18060751 0.77 EGFR (0.49) —
SCHEMBL18060776 0.77 KDM4E (0.48) MAPTHSD17B10KDM4EALDH1A1HPGD
SCHEMBL18060824 0.75 PIK3CA (0.44) MAPTPIK3CAMTORHSD17B10KDM4E
SCHEMBL5765855 0.72 MAPK1 (0.50) MAPTPIK3CAMTORHSD17B10KDM4E
SCHEMBL12806446 0.71 ADRA2C (0.49) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3205647-B1 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2020-05-13 — — EP disclosed
EP-3205647-A2 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Memorial Sloan-Kettering Cancer Center (US) 2017-08-16 — — EP disclosed
EP-2467142-B1 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders SLOAN KETTERING INST CANCER (US) 2016-09-21 — — EP disclosed
Send feedback